Symbol:
Clstn2
Name:
calsyntenin 2
Description:
ENCODES a protein that exhibits calcium ion binding (inferred); INVOLVED IN positive regulation of synapse assembly; positive regulation of synaptic transmission; ASSOCIATED WITH abnormal inhibitory synapse morphology; abnormal spatial reference memory; hyperactivity; ASSOCIATED WITH liver benign neoplasm (ortholog); FOUND IN cell surface; glutamatergic synapse; integral component of postsynaptic density membrane; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-diaminodiphenylmethane; benzo[a]pyrene
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
2900042C18Rik; AI448973; alc-gamma; alcadein-gamma; calsyntenin-2; Cs2; Cst-2; CSTN2; KIAA4134; mKIAA4134
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
CLSTN2 (calsyntenin 2) HGNC
EggNOG, Ensembl, HGNC, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Rattus norvegicus (Norway rat):
Clstn2 (calsyntenin 2) HGNC
Treefam, EggNOG, NCBI, OMA, HomoloGene, Inparanoid, Panther, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Clstn2 (calsyntenin 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
CLSTN2 (calsyntenin 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
CLSTN2 (calsyntenin 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Clstn2 (calsyntenin 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
CLSTN2 (calsyntenin 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Other homologs 2
Homo sapiens (human):
CLSTN1 (calsyntenin 1) HGNC
OrthoDB, OrthoMCL
Homo sapiens (human):
CLSTN3 (calsyntenin 3) HGNC
OrthoMCL
Alliance orthologs 3
Rattus norvegicus (Norway rat):
Clstn2 (calsyntenin 2)
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB)
Homo sapiens (human):
CLSTN2 (calsyntenin 2)
Alliance
DIOPT (Ensembl Compara, HGNC, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, Roundup, TreeFam)
Danio rerio (zebrafish):
si:ch211-276c2.2
Alliance
DIOPT (Ensembl Compara, OrthoFinder, PANTHER, PhylomeDB, TreeFam)
Danio rerio (zebrafish):
clstn2 (calsyntenin 2)
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, Roundup, TreeFam, ZFIN)
Drosophila melanogaster (fruit fly):
Cals
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, Roundup, TreeFam)
Caenorhabditis elegans (roundworm):
casy-1
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, Roundup)
Latest Assembly:
GRCm38 - Mouse Genome Assembly GRCm38
Position:
Mouse Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCm38 9 97,444,395 - 98,033,373 (-) NCBI GRCm38 GRCm38 mm10 GRCm38 MGSCv37 9 97,344,814 - 97,933,586 (-) NCBI GRCm37 mm9 NCBIm37 MGSCv36 9 97,253,747 - 97,842,519 (-) NCBI mm8 Celera 9 96,998,129 - 97,587,251 (-) NCBI Celera Cytogenetic Map 9 E3.3 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
17beta-estradiol decreases expression ISO RGD:621151 6480464 Estradiol results in decreased expression of CLSTN2 mRNA CTD PMID:20068009 17beta-estradiol increases expression ISO RGD:621151 6480464 Estradiol results in increased expression of CLSTN2 mRNA CTD PMID:17010207 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP 6480464 [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene CTD PMID:21212295 2,3,7,8-tetrachlorodibenzodioxine decreases methylation EXP 6480464 Tetrachlorodibenzodioxin results in decreased methylation of CLSTN2 gene CTD PMID:21212295 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane decreases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of CLSTN2 mRNA CTD PMID:18648102 6-propyl-2-thiouracil decreases expression ISO RGD:621151 6480464 Propylthiouracil results in decreased expression of CLSTN2 mRNA CTD PMID:24780913 aflatoxin B1 decreases methylation ISO RGD:1350123 6480464 Aflatoxin B1 results in decreased methylation of CLSTN2 gene CTD PMID:27153756 aflatoxin B1 increases methylation ISO RGD:1350123 6480464 Aflatoxin B1 results in increased methylation of CLSTN2 exon CTD PMID:30157460 benzo[a]pyrene increases expression ISO RGD:621151 6480464 Benzo(a)pyrene results in increased expression of CLSTN2 mRNA CTD PMID:21839799 benzo[a]pyrene multiple interactions EXP 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 benzo[b]fluoranthene multiple interactions EXP 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 benzo[e]pyrene increases methylation ISO RGD:1350123 6480464 benzo(e)pyrene results in increased methylation of CLSTN2 exon CTD PMID:30157460 bisphenol A decreases expression ISO RGD:621151 6480464 bisphenol A results in decreased expression of CLSTN2 mRNA CTD PMID:25181051 bisphenol A multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 cefaloridine decreases expression ISO RGD:621151 6480464 Cephaloridine results in decreased expression of CLSTN2 mRNA CTD PMID:18500788 chrysene multiple interactions EXP 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 dexamethasone multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 diethylstilbestrol increases expression ISO RGD:621151 6480464 Diethylstilbestrol results in increased expression of CLSTN2 mRNA CTD PMID:17010207 dorsomorphin multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1350123 6480464 Doxorubicin results in decreased expression of CLSTN2 mRNA CTD PMID:29803840 endosulfan increases expression ISO RGD:621151 6480464 Endosulfan results in increased expression of CLSTN2 mRNA CTD PMID:29391264 ethanol affects splicing EXP 6480464 Ethanol affects the splicing of CLSTN2 mRNA CTD PMID:30319688 ethanol increases expression EXP 6480464 Ethanol results in increased expression of CLSTN2 mRNA CTD PMID:30319688 fonofos increases methylation ISO RGD:1350123 6480464 Fonofos results in increased methylation of CLSTN2 promoter CTD PMID:22847954 formaldehyde increases expression ISO RGD:1350123 6480464 Formaldehyde results in increased expression of CLSTN2 mRNA CTD PMID:28937961 GW 4064 decreases expression EXP 6480464 GW 4064 results in decreased expression of CLSTN2 mRNA CTD PMID:26655953 indometacin multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 lead(0) affects expression ISO RGD:1350123 6480464 Lead affects the expression of CLSTN2 mRNA CTD PMID:28903495 lead(2+) affects expression ISO RGD:1350123 6480464 Lead affects the expression of CLSTN2 mRNA CTD PMID:28903495 lipopolysaccharide decreases methylation EXP 6480464 Lipopolysaccharides results in decreased methylation of CLSTN2 gene CTD PMID:21212295 lipopolysaccharide multiple interactions EXP 6480464 [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene CTD PMID:21212295 methapyrilene increases methylation ISO RGD:1350123 6480464 Methapyrilene results in increased methylation of CLSTN2 exon CTD PMID:30157460 methylmercury chloride increases expression ISO RGD:1350123 6480464 methylmercuric chloride results in increased expression of CLSTN2 mRNA CTD PMID:28001369 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1350123 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of CLSTN2 mRNA CTD PMID:24810058 N-methylformamide increases expression EXP 6480464 methylformamide analog results in increased expression of CLSTN2 mRNA, methylformamide results in increased expression of CLSTN2 mRNA CTD PMID:17040096 nickel atom decreases expression ISO RGD:1350123 6480464 Nickel results in decreased expression of CLSTN2 mRNA CTD PMID:25583101 panobinostat multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1350123 6480464 panobinostat results in increased expression of CLSTN2 mRNA CTD PMID:26272509 parathion increases methylation ISO RGD:1350123 6480464 Parathion results in increased methylation of CLSTN2 promoter CTD PMID:22847954 phenobarbital affects methylation EXP 6480464 Phenobarbital affects the methylation of CLSTN2 gene CTD PMID:19233941 phenylmercury acetate multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 pirinixic acid decreases expression EXP 6480464 pirinixic acid results in decreased expression of CLSTN2 mRNA CTD PMID:20813756 progesterone increases expression ISO RGD:621151 6480464 Progesterone results in increased expression of CLSTN2 mRNA CTD PMID:20726854 progesterone increases expression EXP 6480464 Progesterone results in increased expression of CLSTN2 mRNA CTD PMID:22238285 SB 431542 multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 sodium arsenite affects methylation ISO RGD:1350123 6480464 sodium arsenite affects the methylation of CLSTN2 gene CTD PMID:28589171 sodium arsenite increases expression ISO RGD:1350123 6480464 sodium arsenite results in increased expression of CLSTN2 mRNA CTD PMID:29301061 sulforaphane decreases expression EXP 6480464 sulforafan results in decreased expression of CLSTN2 mRNA CTD PMID:30529165 terbufos increases methylation ISO RGD:1350123 6480464 terbufos results in increased methylation of CLSTN2 promoter CTD PMID:22847954 Tesaglitazar decreases expression ISO RGD:621151 6480464 tesaglitazar results in decreased expression of CLSTN2 mRNA CTD PMID:21515302 tetraphene multiple interactions EXP 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 titanium dioxide affects expression EXP 6480464 titanium dioxide affects the expression of CLSTN2 mRNA CTD PMID:23557971 trichostatin A increases expression ISO RGD:1350123 6480464 trichostatin A results in increased expression of CLSTN2 mRNA CTD PMID:26272509 trichostatin A multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 triclosan increases expression ISO RGD:1350123 6480464 Triclosan results in increased expression of CLSTN2 mRNA CTD PMID:30510588 troglitazone decreases expression ISO RGD:621151 6480464 troglitazone results in decreased expression of CLSTN2 mRNA CTD PMID:21515302 valproic acid affects expression ISO RGD:1350123 6480464 Valproic Acid affects the expression of CLSTN2 mRNA CTD PMID:25979313 valproic acid decreases expression ISO RGD:621151 6480464 Valproic Acid results in decreased expression of CLSTN2 mRNA CTD PMID:29427782 valproic acid multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1350123 6480464 Valproic Acid results in increased expression of CLSTN2 mRNA CTD PMID:23179753 more ... venlafaxine hydrochloride decreases expression ISO RGD:621151 6480464 Venlafaxine Hydrochloride results in decreased expression of CLSTN2 mRNA CTD PMID:25423262 vinclozolin affects expression ISO RGD:621151 6480464 vinclozolin affects the expression of CLSTN2 mRNA CTD PMID:19015723 
Gene-Chemical Interaction Annotations
